CClinicalTrials.gg
CompletedNCT04307537POIROTUpdated Jan 4, 2023

Post-Operative Imaging After Urethroplasty With Peri-catheter Retrograde Urethrography Or Trial of Voiding With Voiding Cysto-urethrography

A Phase 2 interventional study of Post-urethroplasty urethrography in Urethral Stricture, sponsored by University Hospital, Ghent. Completed at 1 site in Belgium. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-04.

Sponsored by University Hospital, Ghent · Phase 2, Interventional, and Diagnostic

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Study summary

After a reconstructive procedure of the urethra, a transurethral catheter is usually left in place to allow adequate healing of the tissues without exposure to urine. After 7-21 days, depending on several variables (e.g. type of reconstruction, stricture etiology, ...), removal of the transurethral catheter is foreseen. However, in order to do so, the clinician first wants to objectify whether the urethra has indeed healed sufficiently and therefore he/she can rely on early postoperative imaging.

Up until today, there is no clear standard about when and how to do early postoperative imaging and current practices are mainly based on expert opinion and habit. Basically, two strategies can be found amongst different urethroplasty centers: peri-catheter retrograde urethrography (pcRUG) and voiding cysto-urethrography (VCUG). A pcRUG is performed by placing a small caliber tube (e.g. feeding tube 5 Fr) in the meatus urethrae of the patient, next to the transurethral catheter (which remains in place), and injecting contrast alongside the catheter. With a VCUG, contrast is injected through the transurethral catheter, up to the bladder. Thereafter, the catheter is removed and the patient is asked to urinate and thus to pass contrast through the urethra.

The primary end-point of this study is to compare 'the rightful decision to maintain the catheter at the time of imaging' between pcRUG only and pcRUG followed by VCUG in a within-patient fashion.

Read the detailed description

After a reconstructive procedure of the urethra, a transurethral catheter is usually left in place to allow adequate healing of the tissues without exposure to urine. After 7-21 days, depending on several variables (e.g. type of reconstruction, stricture etiology, ...), removal of the transurethral catheter is foreseen. However, in order to do so, the clinician first wants to objectify whether the urethra has indeed healed sufficiently and therefore he/she can rely on early postoperative imaging.

Up until today, there is no clear standard about when and how to do early postoperative imaging and current practices are mainly based on expert opinion and habit. Basically, two strategies can be found amongst different urethroplasty centers: peri-catheter retrograde urethrography (pcRUG) and voiding cysto-urethrography (VCUG). A pcRUG is performed by placing a small caliber tube (e.g. feeding tube 5 Fr) in the meatus urethrae of the patient, next to the transurethral catheter (which remains in place), and injecting contrast alongside the catheter. With a VCUG, contrast is injected through the transurethral catheter, up to the bladder. Thereafter, the catheter is removed and the patient is asked to urinate and thus to pass contrast through the urethra.

In both of the aforementioned imaging modalities, patients are installed similarly on the X-ray table and an antero-posterior X-ray image is made1. In patients with no or insignificant, wisp-like extravasation of contrast, the transurethral catheter can safely be removed. In case of significant contrast extravasation, as defined by Grossgold et al., the catheter is maintained or replaced for another week and one week later, imaging is repeated2.

Both pcRUG and VCUG are not perfect and involve a number of flaws. The main issue with pcRUG is represented by the potential impact of several variables on the image: different levels of pressure in the urethra by different strength of injection, different calibers of tubes through which the contrast is injected, etc. As regards VCUG, an important amount of patients does not achieve to void while being on the X-ray table, which can lead to a long duration of the procedure or even no imaging at all. Another important problem is the fact that if the patient has a significant extravasation of contrast, the catheter needs to be replaced through the freshly reconstructed, and apparently still leaking, urethra. This may be difficult and is often bothersome for the patient.

Given the drawbacks mentioned above, a combination of both techniques can be administered to overcome the flaws of each separate imaging modality and could as such be considered the standard of care in early postoperative imaging after urethroplasty. However, the combination of both techniques includes a higher exposure to radiation than one separate technique and one could wonder what the added value of VCUG after pcRUG is and whether or not this is worth the extra exposure to radiation. To date, there is no such data and a wide variability of strategies is used in the different urethroplasty practices worldwide.

Against this background, the primary end-point of this study is to compare 'the rightful decision to maintain the catheter at the time of imaging' between pcRUG only and pcRUG followed by VCUG in a within-patient fashion.

02

Conditions studied

  • Urethral Stricture

Browse trials for

03

In context

Urethral Stricture

68 studies on the registry are indexed under Urethral Stricture; 23 are open to participants now.

This study's enrollment of 80 is above the median of 60 across 53 interventional studies indexed under Urethral Stricture.

Browse Urethral Stricture studies →

Lead sponsor

University Hospital, Ghent is the lead sponsor of 665 studies on the registry; 156 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Voluntarily signed written informed consent according to the rules of Good Clinical Practice (Declaration of Helsinki) and national regulations (Appendix B).
  • Age ≥ 18 years.
  • Male patient.
  • Anterior urethral stricture disease (penile, bulbar, penobulbar and panurethral strictures are allowed).
  • Procedure was ended with leaving a transurethral catheter in place with foreseen catheter removal and early postoperative imaging after x days.

Exclusion criteria

Exclusion Criteria:

  • Absence of signed written informed consent (Appendix B).
  • Age \< 18 years.
  • Female patients.
  • Transgender patients.
  • Posterior urethral stenosis
  • Bladder neck reconstruction
  • Patients in which no catheter has been left in place at the end of the procedure.
  • Patients in which there is no need for early postoperative imaging, upon discretion of the treating clinician.
05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    pcRUG

    Peri-catheter retrograde urethrography

    Procedure: Post-urethroplasty urethrography

  • Active comparator
    VCUG

    Voiding cysto-urethrography

    Procedure: Post-urethroplasty urethrography

Interventions

  • ProcedurePost-urethroplasty urethrography

    Imaging of the urethra after reconstructive surgery to identify contrast leakage (no, insignificant, signficant).

06

What researchers measure

Primary outcomes

  1. Percentage of 'rightful decision to maintain the catheter at the time of imaging' between pcRUG only and VCUG.

    In other words, the amount of catheters maintained during the investigation divided by the number of significant extravasations requiring perpetuated catheter stay.

    Time frame: 1 day (day of original investigation)

Secondary outcomes

  1. Difference in radiation exposure between pcRUG and VCUG expressed in mGy/(cm*cm)

    Difference in dose of radiation exposure will be assessed with the Mann-Whitney U-test.

    Time frame: 1 day (moment of original investigation)

  2. Difference in the amount of significant extravasations that is picked up with pcRUG versus VCUG.

    Results of both pcRUG and VCUG will be shown to the treating clinician at least 4 weeks after the original investigation and the clinician will have to choose between 'no or insignificant contrast leakage' versus 'significant contrast leakage'.

    Time frame: Results of both pcRUG and VCUG will be shown to the treating clinician at least 4 weeks after the original investigation and the clinician will have to choose between 'no or insignificant contrast leakage' versus 'significant contrast leakage'.

  3. Intra-observer variability of both pcRUG and VCUG

    Reproducibility will be assessed with intraclass correlation coefficients. A threshold of \>0.70 will be used as threshold for good intraclass correlation and thus good reproducibility.

    Time frame: First blinded assessment (at least 4 weeks after original investigation) versus second blinded assessment another 4 weeks later.

  4. Inter-observer variability of both pcRUG and VCUG

    Inter-observer variability will be assessed with Cohen's kappa. A threshold of \>0.70 will be used for good inter-observer variability

    Time frame: Two experienced clinicians will be compared regarding decision making during the first blinded assessment (at least 4 weeks after the original investigation).

  5. Amount of patients unable to void while being on the X-ray table

    During VCUG, patients have to void after catheter removal to allow urethral imaging. Often, patients are unable to void while on the X-ray table.

    Time frame: 1 day (moment of original investigation)

07

Study locations

1 site
  • Dept. of Urology, Ghent University Hospital
    Ghent, East-Flanders 9000, Belgium
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04307537
Lead sponsor
University Hospital, Ghent
Responsible party
Sponsor
First posted
Mar 13, 2020
Start date
Jan 21, 2020
Primary completion
Sep 1, 2021
Completion
Sep 1, 2021
Last update
Jan 4, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion